Clinical Trials Multicenter, randomized controlled trial: To verify the efficacy and safety of AOD 9604 in humans
At Perfect B in Doral, FL, every peptide therapy protocol is clinically supervised and tailored to the individual patient
BPC-157 can be viewed in the context of fibroblast activity, angiogenesis and tissue responses in preclinical models, while the TB-500 / thymosin beta-4 in the context of the actin cytoskeleton, the monomeric actin pool, cell motility and the formation of vascular structures
This selectivity allows for neuroprotection and tissue repair without the thrombotic risks of EPO
TB-500 vs BPC-157: how they differ TB-500 vs BPC-157 -both are discussed in the context of recovery and tissue support, but they are different molecules with different mechanisms
Every subsequent dose is double what you think it is